9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

Estimated reading time: < 1 min

Condition: Esophageal Carcinoma

Estimated Enrollment: 5

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Change in mouth pain using a 0 to 10 numerical analogue scale,  Incidence of any grade 3 or higher adverse events using Common Terminology Criteria for Adverse Events (CTCAE),  Incidence of any grade 3 or higher adverse event rates using Radiation Therapy Oncology Group, Adverse event rates using Patient Reported Outcomes (PROs) on Day 1 and Day 3 crossover

Interventions: Doxepin Hydrochloride, Placebo

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double (Participant, Investigator),Primary Purpose: Supportive Care

Primary Completion Date: May 29, 2015

Completion Date: November 6, 2017

Last  Posted Date: November 16, 2018

Location: Mayo Clinic, Rochester, Minnesota, United States

Website Link: https://ClinicalTrials.gov/show/NCT02062632

Was this article helpful?
Dislike 0